cas 40794-04-5|| where to buy 4-Chloro-2-methoxy-1-methylbenzene

Nom du produit:4-Chloro-2-methoxy-1-methylbenzene

IUPAC Name:4-chloro-2-methoxy-1-methylbenzene

Unité d'emballage	Stock disponible	Prix($)
CM283380-5g	in stock	ƈƈ
CM283380-10g	in stock	ƚǸŌ
CM283380-25g	in stock	ƚƿŤ
CM283380-100g	in stock	ƈƚľ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 40794-04-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:40794-04-5; Formule moléculaire:C8H9ClO; Point de fusion:-; Code SMILES:CC1=CC=C(Cl)C=C1OC; Densité:

: Numéro de catalogue:CM283380; Poids moléculaire:156.61; Point d'ébullition:204°C at 760 mmHg; N° Mdl:MFCD07368289; Stockage:Store at 2-8°C.

: Crinecerfont; The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.